Bristol-Myers Squibb Co vs iShares Semiconductor ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.68 (market cap $116.30B), while iShares Semiconductor ETF trades at $550.57. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares Semiconductor ETF pays none. Which is the better fit depends on your goals.
| BMY | SOXX | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $655.01 |
52-Week Low | $42.60 | $236.93 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SOXX trades at $553.1, down 4.82% over 24 hours amid a broader semiconductor selloff. Technical indicators show a bearish trend with support at $530 and resistance at $557. The ETF has delivered exceptional YTD performance with 93.3% gains through July 6, 2026, driven by AI demand, though recent volatility has erased some gains. A dividend of $0.28 is scheduled for June 2026.
Outlook remains mixed with strong AI-driven growth potential offset by sector volatility and Michael Burry's bearish bet. Key risks include semiconductor cyclicality and geopolitical tensions. The ETF offers diversified exposure to leading chip companies but faces near-term pressure from the recent correction.
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →